Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
about
Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adultsAllogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Transplant outcomes in acute leukemia. I.Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Hematopoietic stem cell transplantation for MDS.High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationEffect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantationAllogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord bloodComparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic reviewBone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.High-dose cyclophosphamide for graft-versus-host disease prevention.Selecting donor recipients.Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohortEffect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysisRisk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host diseaseChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Risk factors for acute GVHD and survival after hematopoietic cell transplantationPeripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.Evaluation of prognostic factors among patients with chronic graft-versus-host disease.Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation.A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant.Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.The hematopoietic system in the context of regenerative medicine.A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantationLate Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Methods for equivalence and noninferiority testing.Peripheral-blood stem cells versus bone marrow from unrelated donorsDonor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice.Role of allogeneic transplantation in chronic myeloid leukemia.Current clinical management of Fanconi anemia.
P2860
Q24195048-01F71808-ED2C-4F8F-86E6-C85380D52DF5Q30274942-7B643BB2-1D26-44FA-A489-B2F95269BA04Q33621502-0758226E-0781-4390-8970-EBD59259C510Q33685495-2E159709-3768-4B8A-BEA8-AF4BE99F8890Q33767314-47B5E6B0-629F-4651-A279-9E2FFBF9589FQ33806054-29F1AC81-2F09-4A82-93A5-C318DD3A9802Q33813439-9114FA36-04E8-4F92-92AA-FBE6097619B2Q33822026-AEBF9E1E-8B9B-4FF2-9141-FD7BC592DC10Q33941128-547E4CE7-99E4-421F-AF77-6C2EF48B7105Q34033553-5F0CA2C9-534A-4BAC-BC6E-034C2ABDE5C4Q34374133-BDF4E9F5-3331-4C6D-AB3F-CB1A254C96E7Q34707280-8758382D-CDF8-457E-B92C-BBDDC2C1C624Q34770016-D12CB66A-C76F-4D2E-88E2-E49096B9736BQ34996663-77AB6F3F-CB66-4734-8746-A740BB9B377CQ35042790-5CACD5DA-5377-4C5E-B508-F72D6903C464Q35042830-E95B8599-C70C-416D-8CF0-39EADD702B71Q35067642-30FD602D-08C8-474B-8229-1445C31AD246Q35103562-0B3FCC2A-CA77-4FF3-941D-3303E31A09A3Q35110765-AD74A51C-B727-4A5C-9492-0FEE3783F98BQ35170474-B4165822-23AB-47D8-A8AF-AD8831FD5F04Q35177449-1165CAA2-C708-412C-AD9C-DB47BBC895CCQ35185685-51C5F5E2-19BB-4172-A677-DA1ED0AC40C5Q35485880-395DA1CD-3F38-4A2A-A807-57B1B8BF8125Q35633858-77E3B430-9682-43C3-918D-48692F006344Q35651735-A65B2E24-3075-448A-A922-AE916A38E47DQ35673530-5B92B444-6733-4661-872D-CE1527DBAD03Q36055266-FBE30A8C-6FF8-457E-89F6-EAFB6C2048C1Q36133013-D34C475E-423A-4F9C-AD02-1246CD3E28D3Q36560134-929C1048-53D0-42E5-8AD8-823CDBDA99F2Q36592428-169571B6-3BEC-4BBB-A783-FB03FD7C607EQ36596897-6A9D2A22-9C9F-40FE-8A89-9ADDBCA36473Q36627127-CDFF2F0A-376E-4F8F-9AE0-93E034830516Q36941032-1ACCCCE2-B05E-49D7-A603-885A48186EE0Q37041729-F5DCC041-5A31-44EB-95E1-CBE304F9B8E5Q37239244-538F24D6-C0B0-4739-94D8-476CB644F346Q37276359-D1607041-7E66-4DC8-B745-78FC4C0181F2Q37372806-2CC1072E-2E65-4D66-8D40-E28326A2E8C9Q37381690-D80A7726-BD3F-406A-82DD-1A0BEB2137D2Q37810113-F2228E12-7025-47E9-AD5D-0B1EEC03DE6FQ38059251-C472FEFB-83CF-4952-A9D6-836DF74AD10C
P2860
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Peripheral blood grafts from u ...... ease without improved survival
@ast
Peripheral blood grafts from u ...... ease without improved survival
@en
type
label
Peripheral blood grafts from u ...... ease without improved survival
@ast
Peripheral blood grafts from u ...... ease without improved survival
@en
prefLabel
Peripheral blood grafts from u ...... ease without improved survival
@ast
Peripheral blood grafts from u ...... ease without improved survival
@en
P2093
P2860
P1476
Peripheral blood grafts from u ...... ease without improved survival
@en
P2093
Adrian P Gee
Brent R Logan
Claudio Anasetti
Daniel J Weisdorf
David Stroncek
Dennis L Confer
John E Wagner
John R Wingard
Mary Eapen
Mary M Horowitz
P2860
P304
P356
10.1016/J.BBMT.2007.08.006
P577
2007-10-10T00:00:00Z